CO001 / CellOrigin Biotech - LARVOL DELTA

Development of a novel bifunctional anti-CD47 fusion protein with improved efficacy and a favorable safety profile. (PubMed, Mol Cancer Ther) - "The ability of CO-005 to trigger strong PCCD while preserving conventional immune responses provides a novel and promising approach for CD47-targeted cancer therapy. Its favorable safety profile, observed in both in vitro and ex vivo studies, positions CO-005 as a promising candidate with potential therapeutic advantages over existing anti-CD47 treatments."

Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • SIRPA

The importance of innovative design in enhancing the safety of the next generation anti-CD47 therapeutics (SITC 2024) - "CO-005 effectively targets and eradicates cancer cells similar to parental CO-001 but offers a significantly improved safety profile...Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Oncology • ANXA5 • CD47 • SIRPA

The importance of innovative design in enhancing the safety of the next generation anti-CD47 therapeutics (SITC 2024) - "CO-005 effectively targets and eradicates cancer cells similar to parental CO-001 but offers a significantly improved safety profile...Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Oncology • ANXA5 • CD47 • SIRPA